KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash & Equivalents (2018 - 2026)

Castle Biosciences' Cash & Equivalents history spans 8 years, with the latest figure at $116.7 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 2.51% to $116.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $116.7 million, a 2.51% decrease, with the full-year FY2025 number at $116.7 million, down 2.51% from a year prior.
  • Cash & Equivalents hit $116.7 million in Q4 2025 for Castle Biosciences, up from $85.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CSTL hit a ceiling of $407.0 million in Q1 2021 and a floor of $82.2 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $173.3 million across 5 years, with a median of $115.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 312.54% in 2021 and later plummeted 64.9% in 2023.
  • Tracing CSTL's Cash & Equivalents over 5 years: stood at $329.6 million in 2021, then crashed by 62.7% to $122.9 million in 2022, then dropped by 19.61% to $98.8 million in 2023, then increased by 21.11% to $119.7 million in 2024, then dropped by 2.51% to $116.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for CSTL at $116.7 million in Q4 2025, $85.6 million in Q3 2025, and $82.2 million in Q2 2025.